目的 探讨注射用重组人生长激素联合注射用头孢曲松钠治疗患儿新生儿败血症的临床疗效。方法 选取2018年5月—2021年1月许昌市中心医院收治的86例新生儿败血症患儿作为研究对象，根据随机数字表法将86例患儿分为对照组和治疗组，每组各43例。对照组患儿微泵静脉滴注注射用头孢曲松钠20 mg/kg，1次/d。治疗组在对照组治疗的基础上腹部肌注注射用重组人生长激素，剂量0.1 IU/kg，1次/2 d。两组患儿连续治疗8 d。观察两组患儿的临床疗效，比较两组患儿症状体征改善时间，以及血清中C反应蛋白（CRP）、白细胞介素-6（IL-6）、降钙素原（PCT）、CD4⁺/CD16⁺、CD3⁺、CD4⁺水平。结果 治疗后，治疗组的总有效率（95.35%）高于对照组（81.40%），组间差异有显著性（P<0.05）。治疗后，治疗组的体温恢复时间、拒奶消失时间、住院时间均明显短于对照组（P<0.05）。治疗后，两组的血清CRP、IL-6、PCT水平明显降低（P<0.05）；且治疗组的血清CRP、IL-6、PCT水平低于对照组（P<0.05）。治疗后，治疗组的CD4⁺/CD16⁺较治疗前显著降低，CD3⁺、CD4⁺较治疗前显著升高（P<0.05）；治疗组患者的CD4⁺/CD16⁺明显低于对照组，CD3⁺、CD4⁺高于对照组（P<0.05）。结论 注射用重组人生长激素联合注射用头孢曲松钠可提高新生儿败血症的疗效，有助于改善临床症状，降低炎症反应，改善患儿的免疫功能，药物安全性良好。

Objective To investigate the therapeutic effect of Recombinant Human Growth Hormone for injection combined with Ceftriaxone Sodium for injection in treatment of neonatal sepsis. Methods Children (86 cases) with neonatal sepsis in Xuchang Central Hospital from May 2018 to January 2021 were randomly divided into control and treatment groups, and each group had 43 cases. Children in the control group were micro pump intravenous drip administered with Ceftriaxone Sodium for injection, 20 mg/kg, once daily. Children in the treatment group were abdominal im administered with Recombinant Human Growth Hormone for injection on the basis of the control group, 0.1 IU/kg, once every 2 days. Children in two groups were treated for 8 d. After treatment, the clinical efficacies were evaluated, and the improvement time of symptom, and the levels of CRP, IL-6, PCT, CD4⁺/CD16⁺, CD3⁺, and CD4⁺ in two groups were compared. Results After treatment, the total effective rate of the treatment group (95.35%) was higher than that of the control group (81.40%), and there was significant differences between groups (P < 0.05). After treatment, the recovery time of body temperature, the disappearance time of milk refusal, and the length of hospital stay in the treatment group were shorter than those in the control group (P < 0.05). After treatment, serum levels of CRP, IL-6, and PCT in two groups were significantly decreased (P < 0.05). After treatment, the serum levels of CRP, IL-6, and PCT in the treatment group were lower than those in the control group (P < 0.05). After treatment, the CD4⁺/CD16⁺ in the treatment group was significantly lower than that before treatment, but the CD3⁺ and CD4⁺ in the treatment group were significantly higher than that before treatment (P< 0.05). And the CD4⁺/CD16⁺ in the treatment group was lower than that in the control group, but the CD3⁺ and CD4⁺ in the treatment group were higher than those in the control group (P < 0.05). Conclusion Recombinant Human Growth Hormone for injection combined with Ceftriaxone Sodium for injection can improve the curative effect of neonatal sepsis, help to improve clinical symptoms, reduce inflammatory reaction, improve children's immune function, with good safety.

R973;R985

河南省医学科技攻关计划（联合共建项目）（LHGJ20191401）